A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer.

CONCLUSIONS: The BP regimen was active and well tolerated in the real-world clinical settings. As many as 28.9% of patients who received the initial dose of 90 mg/m(2) required a dose reduction of paclitaxel by 20 mg/m(2). Therefore, there is a need to find a therapeutic regimen that is less likely to result in dose reductions for patients with MBC who undergo a BP regimen using the initial paclitaxel dose of 90 mg/m(2).
PMID: 29142182 [PubMed - in process]

Source: Journal of Nippon Medical School - November 18, 2017 Category: Universities & Medical Training Authors: Yamada H, Inoue K, Nagai SE, Nakai M, Arisawa F, Ueda H, Saito T, Ninomiya J, Kuroda T, Sakurai T, Kodama H, Kimizuka K, Hata S, Kai T, Kurosumi M, SBCCSG investigators Tags: J Nippon Med Sch Source Type: research